Home > Products > Antibodies > Biosimilars

Research Grade Porgaviximab (VK623046)

Datasheet Share product Copy info

Research Grade Porgaviximab

Research Grade Porgaviximab

Price(USD): $

Spec:

100ug
1mg

Number:

Contact us

Overview
Images
References
Datasheet

Overview

Catalog No.	VK623046
Description	Porgaviximab (VK623046) is a research-grade recombinant antibody targeting Envelope glycoprotein. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Zaire ebolavirus
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Chimeric
Isotype	IgG1, kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	Envelope glycoprotein, GP1, 2, GP, Shed GP, GP1, 2-delta, GP1, GP2, GP
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q05320
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names	c2G4-N, 1792982-55-8
Background	Envelope glycoprotein (GP) is a ~74 kDa protein. Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, down-regulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity) (Probable). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes. 1. Simmons, G. et al. (2002) Journal of virology 76, 2518-28. PMID: 11836430 2. Takada, A. et al. (2000) Virology 278, 20-6. PMID: 11112476 3. Iampietro, M. et al. (2017) PLoS pathogens 13, e1006397. PMID: 28542576 4. Edri, A. et al. (2018) Frontiers in immunology 9, 1428. PMID: 30013549 5. Vande Burgt, NH. et al. (2015) Viruses 7, 5587-602. PMID: 26516900 6. Brinkmann, C. et al. (2016) Journal of virology 90, 11075-11086. PMID: 27707924 7. González-Hernández, M. et al. (2018) Journal of virology 92. PMID: 29669839 8. Rizk, MG. et al. (2017) Journal of virology 91. PMID: 28878074
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Porgaviximab

References

Datasheet

Research Grade Porgaviximab.pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list

Research Grade Porgaviximab